What Schedule III Means for Cannabis

For decades, cannabis has sat in the same federal category as heroin and cocaine under the Controlled Substances Act: Schedule I. That classification meant the federal government considered cannabis to have a high potential for abuse and “no currently accepted medical use.” For an industry built around wellness, plant medicine, and patient relief, that label has always felt disconnected from reality.

Now, one of the biggest shifts in cannabis history is happening.

The U.S. Department of Justice and DEA have officially moved certain cannabis products, specifically FDA-approved products and state-licensed medical marijuana products, from Schedule I to Schedule III, while beginning the broader process of reviewing full cannabis rescheduling. This is a major federal policy shift that could change research, taxes, banking, and the long-term future of the cannabis industry.

But what does that actually mean?

Let’s break it down.

What Is Schedule I vs. Schedule III?

A Schedule I drug is considered to have no accepted medical use and a high potential for abuse. Cannabis has been grouped here for years alongside substances like heroin and cocaine.

A Schedule III drug, on the other hand, is recognized as having medical value and a lower abuse potential. Other Schedule III substances include ketamine, testosterone products, and Tylenol with codeine.

This move does not federally legalize cannabis.

Adult-use recreational cannabis remains federally illegal, and state laws still control how consumers access products. But federally recognizing cannabis as having medical value is a massive step forward.

Why This Matters for Cannabis Businesses

One of the biggest wins is tax relief.

For years, cannabis operators have been crushed by IRS Code Section 280E, which prevents businesses handling Schedule I or II substances from deducting normal business expenses like payroll, rent, and marketing.

That means many cannabis businesses were paying extremely high effective tax rates, sometimes over 70%.

By moving qualifying medical cannabis operations into Schedule III, those businesses may now be able to take standard business deductions like any normal company. This could dramatically improve profitability, cash flow, and long-term sustainability.

For brands, dispensaries, and operators, this is not just paperwork, it could be the difference between surviving and scaling.

Why This Matters for Research

Schedule I status created huge barriers for cannabis research.

Scientists faced heavy DEA restrictions, limited approved supply sources, and massive compliance hurdles just to study the plant. This slowed progress in understanding cannabis for pain management, epilepsy, sleep, anxiety, recovery, and countless other wellness applications.

Schedule III opens the door for more legitimate clinical research and better healthcare integration.

That means stronger science, more physician confidence, better patient outcomes, and eventually more mainstream acceptance of cannabis as medici

What It Does NOT Mean

This is where many people get confused.

Rescheduling does not mean:

• Federal legalization

• Interstate cannabis commerce

• Recreational cannabis approval nationwide

• Automatic banking reform

• Expungement of prior cannabis convictions

Those bigger issues still require separate legislation and reform. This is progress, but it is not the finish line.

The Bigger Picture

Cannabis moving to Schedule III is more than policy, it is validation.

It signals that the federal government is finally starting to catch up with what patients, operators, and advocates have known for years: cannabis has real therapeutic value.

For brands like WaxNax and the people who support this culture every day, this shift creates more legitimacy, more opportunity, and a stronger future for the industry.

It also means the conversations around cannabis are changing from stigma to strategy. From survival to scale. From underground to undeniable. That is a win for everyone building in this space.

If you want to read more about the latest federal cannabis rescheduling updates, check out this article from the U.S. Department of Justice: Justice Department Places FDA-Approved Marijuana Products in Schedule III

The future of cannabis is being written right now. And for the first time in a long time, federal policy is finally starting to reflect the truth.

Thats a wrap for this weeks Digest.

Until next time... Happy Dabbing, Everyone!

- The WaxNax Team